Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
From awareness to advocacy, Karen Bonds has come full circle—turning her battle into a mission to ensure that no one fights breast cancer alone.
Flossmoor resident and cancer survivor Ann Jackson launched the Center for Food Equity in Medicine at Flossmoor Community ...
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
Questions about sex and intimacy often go unanswered for people with cancer. It's a glaring problem, especially for the ...
If you have been diagnosed with metastatic breast cancer, resources like support groups, counseling, financial assistance, and online communities can help.
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback